Autolus Therapeutics plc (AUTL) stock
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Earnings
Autolus Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Autolus Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 26, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | $41.24M | +95.4% | -$0.21 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | $45.69M | +118.6% | -$0.15 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026before the open | $26.20M | +191.1% | -$0.27 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 27, 2026before the open | $24.29M | – | -$0.34 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | $21.10M | – | -$0.30 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | $20.90M | – | -$0.18 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $9.00M | -10.8% | -$0.26 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | -$0.31 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | – | – | -$0.22 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 17, 2024before the open | $10.09M | – | -$0.24 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Autolus Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| AUCATZYL net product revenue | FY2026 | $150.00M | – | New | Nov 10, 2026 |
| AUCATZYL net product revenue | FY2026 | $140.00M – $150.00M | $120.00M – $135.00M | Raised | Aug 11, 2026 |
Guidance history
Every forecast Autolus Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2026 | AUCATZYL net product revenue | FY2026 | $150.00M | New |
| Aug 11, 2026 | AUCATZYL net product revenue | FY2026 | $140.00M – $150.00M | Raised |
| May 14, 2026 | AUCATZYL net product revenue | FY2026 | $120.00M – $135.00M | Reaffirmed |
| Mar 27, 2026 | AUCATZYL net product revenue | FY2026 | $120.00M – $135.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Autolus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- News
- News
- News
- Results
- Results
- Update
- Update
- Results
- Results
- Update
See a number that looks wrong?